Intravacc and BCHT enter into license agreement for production of a Hib conjugate vaccine
Bilthoven, the Netherlands, 12 November 2018
Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China. By combining their strengths, the two parties can together lower the incidence of this vaccine preventable disease in China.
Through this agreement, BCHT obtained Intravacc’s unique Hib conjugate technology to further develop, produce and sell the vaccine. The vaccine consists of a Hib polysaccharide (poly-ribosylribitol phosphate, PRP) coupled to tetanus toxoid that has shown to be effective in preventing the disease. The Intravacc Hib vaccine technology has already been used for the vaccination of 100s of millions of children. The license agreement between Intravacc and BCHT will now help to reduce the incidence of Hib in Chinese children.
Of the 6 types of H influenzae, type B is responsible for more than 90% of systemic infections. Hib can cause serious illness like acute lower respiratory tract infection and bacterial meningitis. In China, for children under age of 5 years old, the incidence of meningitis caused by Hib was reported in a survey about 10.7/100 000 annually; 9.7% of these cases were fatal, and 21.4% of survivors suffered from neurological or psychological problems. The agreement between Intravacc and BCHT will help to bring this number down considerably.
‘’It’s great to hear that the innovative work of our researchers at Intravacc will contribute to the prevention of Hib in China. We are proud to partner with BCHT to prevent this disease.” said Mr Nico Oudendijk, General Director of Intravacc.
NOTE TO EDITORS
About Intravacc: Intravacc, based in Bilthoven, the Netherlands, is an established R&D organization with more than 100 years’ experience in the development and optimization of vaccines, vaccine processes and vaccine technologies. Intravacc has state-of-the-art research and production facilities and its aim is to substantially reduce development risks and costs of new vaccines in order to contribute to global health and equity in access to vaccines worldwide.